This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Desch, C. E. Articles by Somerfield, M. R. Search for Related Content PubMed PubMed Citation Articles by Desch, C. E. Articles by Somerfield, M. R. Social Bookmarking                            What's this?

Recommended Colorectal Cancer Surveillance Guidelines by the American Society of Clinical Oncology

From the American Society of Clinical Oncology. (ASCO) Colorectal Cancer Surveillance Panel; C.E.D. and A.B.B. are co-chairs of this panel. Adopted by the ASCO Board of Directors on November 13, 1998.

Address reprint requests to Jennifer J. Padberg, American Society of Clinical Oncology, Health Services Research, 225 Reinekers Lane, Suite 650, Alexandria, VA 22314; email padbergj{at}asco.org

ABSTRACT

OBJECTIVE: To determine the most effective, evidence-based, postoperative surveillance strategy for the detection of recurrent colon and rectal cancer. Tests are to be recommended only if they have an impact on the outcomes listed below.

POTENTIAL INTERVENTION: All tests described in the literature for postoperative monitoring were considered. In addition, the data were critically evaluated to determine the optimal frequency of monitoring.

OUTCOMES: Outcomes of interest included overall and disease-free survival, quality of life, toxicity reduction, and cost-effectiveness. The American Society of Clinical Oncology (ASCO) Colorectal Cancer Surveillance Expert Panel was guided by the principle of cost minimization, ie, when two strategies were believed to be equally effective, the least expensive test was recommended.

EVIDENCE: A complete MEDLINE search was performed of the past 20 years of the medical literature. Keywords included colorectal cancer, follow-up, and carcinoembryonic antigen, as well as the names of the specific tests. The search was broadened by articlesfrom the tumor marker ASCO panel literature search, as well as from bibliographies of selected articles.

VALUES: Levels of evidence and guideline grades were rated by a standard process. More weight was given to studies that tested a hypothesis directly relating testing to one of the primary outcomes in a randomized design.

BENEFITS/HARMS/COSTS: The possible consequences of false-positive and false-negative tests were considered in evaluating a preference for one of two tests that provide similar information. Cost alone was not a determining factor.

RECOMMENDATIONS: The expert panel's recommended postoperative monitoring schema is discussed in this article.

VALIDATION: Five outside reviewers, the ASCO Health Services Research Committee, and the ASCO Board of Directors examined this document.

SPONSOR: American Society of Clinical Oncology.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. L. Malin, E. C. Schneider, A. M. Epstein, J. Adams, E. J. Emanuel, and K. L. Kahn Results of the National Initiative for Cancer Care Quality: How Can We Improve the Quality of Cancer Care in the United States? J. Clin. Oncol., February 1, 2006; 24(4): 626 - 634. [Abstract] [Full Text] [PDF]

				F. Rodriguez-Moranta, J. Salo, A. Arcusa, J. Boadas, V. Pinol, X. Bessa, E. Batiste-Alentorn, A. M. Lacy, S. Delgado, J. Maurel, et al. Postoperative Surveillance in Patients With Colorectal Cancer Who Have Undergone Curative Resection: A Prospective, Multicenter, Randomized, Controlled Trial J. Clin. Oncol., January 20, 2006; 24(3): 386 - 393. [Abstract] [Full Text] [PDF]

				R. M. Goldberg Intensive Surveillance After Stage II or III Colorectal Cancer: Is It Worth It? J. Clin. Oncol., January 20, 2006; 24(3): 330 - 331. [Full Text] [PDF]

				S. Rolnick, S. H. Alford, G. P. Kucera, K. Fortman, M. U. Yood, M. Jankowski, and C. C. Johnson Racial and Age Differences in Colon Examination Surveillance Following a Diagnosis of Colorectal Cancer J Natl Cancer Inst Monographs, November 1, 2005; 2005(35): 96 - 101. [Abstract] [Full Text] [PDF]

				N. L. Keating, M. B. Landrum, E. Meara, P. A. Ganz, and E. Guadagnoli Do Increases in the Market Share of Managed Care Influence Quality of Cancer Care in the Fee-For-Service Sector? J Natl Cancer Inst, February 16, 2005; 97(4): 257 - 264. [Abstract] [Full Text] [PDF]

				H. Kattlove and R. J. Winn Ongoing Care of Patients After Primary Treatment for Their Cancer CA Cancer J Clin, May 1, 2003; 53(3): 172 - 196. [Abstract] [Full Text] [PDF]

				C. C. Earle, E. Grunfeld, D. Coyle, M. C. Cripps, and H. S. Stern Cancer physicians' attitudes toward colorectal cancer follow-up Ann. Onc., March 1, 2003; 14(3): 400 - 405. [Abstract] [Full Text] [PDF]

				P. M. Calvert and H. Frucht The Genetics of Colorectal Cancer Ann Intern Med, October 1, 2002; 137(7): 603 - 612. [Abstract] [Full Text] [PDF]

				R. J. Green, J. P. Metlay, K. Propert, P. J. Catalano, J. S. Macdonald, R. J. Mayer, and D. G. Haller Surveillance for Second Primary Colorectal Cancer after Adjuvant Chemotherapy: An Analysis of Intergroup 0089 Ann Intern Med, February 19, 2002; 136(4): 261 - 269. [Abstract] [Full Text] [PDF]

				C. C. Raggi, A. Calabro, D. Renzi, V. Briganti, F. Cianchi, L. Messerini, R. Valanzano, M. C. Smith, C. Cortesini, F. Tonelli, et al. Quantitative Evaluation of Somatostatin Receptor Subtype 2 Expression in Sporadic Colorectal Tumor and in the Corresponding Normal Mucosa Clin. Cancer Res., February 1, 2002; 8(2): 419 - 427. [Abstract] [Full Text] [PDF]

				S. K. Libutti, H. R. Alexander Jr, P. Choyke, D. L. Bartlett, S. L. Bacharach, M. Whatley, F. Jousse, W. C. Eckelman, K. Kranda, R. D. Neumann, et al. A Prospective Study of 2-[18F] Fluoro-2-Deoxy-D-Glucose/Positron Emission Tomography Scan, 99mTc-Labeled Arcitumomab (CEA-Scan), and Blind Second-Look Laparotomy for Detecting Colon Cancer Recurrence in Patients With Increasing Carcinoembryonic Antigen Levels Ann. Surg. Oncol., December 1, 2001; 8(10): 779 - 786. [Abstract] [Full Text] [PDF]

				H. Nelson, N. Petrelli, A. Carlin, J. Couture, J. Fleshman, J. Guillem, B. Miedema, D. Ota, and D. Sargent Guidelines 2000 for Colon and Rectal Cancer Surgery J Natl Cancer Inst, April 18, 2001; 93(8): 583 - 596. [Abstract] [Full Text] [PDF]

				R. C. Bast Jr, P. Ravdin, D. F. Hayes, S. Bates, H. Fritsche Jr, J. M. Jessup, N. Kemeny, G. Y. Locker, R. G. Mennel, and M. R. Somerfield 2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology J. Clin. Oncol., March 15, 2001; 19(6): 1865 - 1878. [Abstract] [Full Text] [PDF]

				A. B. Benson III, C. E. Desch, P. J. Flynn, C. Krause, C. L. Loprinzi, B. D. Minsky, N. J. Petrelli, D. G. Pfister, T. J. Smith, and M. R. Somerfield 2000 Update of American Society of Clinical Oncology Colorectal Cancer Surveillance Guidelines J. Clin. Oncol., October 20, 2000; 18(20): 3586 - 3588. [Full Text] [PDF]